Concepts (90)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 4 | 2016 | 927 | 1.260 |
Why?
|
| AIDS-Related Opportunistic Infections | 3 | 2016 | 68 | 0.720 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2016 | 3 | 0.530 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2016 | 9 | 0.520 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2016 | 9 | 0.520 |
Why?
|
| AIDS Dementia Complex | 1 | 2016 | 12 | 0.520 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2016 | 28 | 0.520 |
Why?
|
| Neoplasms | 2 | 2016 | 1262 | 0.510 |
Why?
|
| Viral Load | 1 | 2016 | 229 | 0.490 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2016 | 94 | 0.480 |
Why?
|
| HIV Protease Inhibitors | 1 | 2016 | 106 | 0.480 |
Why?
|
| RNA, Viral | 1 | 2016 | 265 | 0.470 |
Why?
|
| Mass Screening | 2 | 2016 | 662 | 0.440 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 538 | 0.360 |
Why?
|
| Hypertension | 1 | 2016 | 603 | 0.350 |
Why?
|
| Primary Health Care | 1 | 2016 | 660 | 0.340 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 831 | 0.300 |
Why?
|
| Toxoplasmosis, Cerebral | 2 | 2016 | 6 | 0.230 |
Why?
|
| Amphotericin B | 1 | 2003 | 22 | 0.220 |
Why?
|
| Antifungal Agents | 1 | 2003 | 116 | 0.200 |
Why?
|
| Comorbidity | 2 | 2016 | 1099 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 713 | 0.130 |
Why?
|
| Lamivudine | 1 | 2016 | 7 | 0.130 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2016 | 8 | 0.130 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2016 | 3 | 0.130 |
Why?
|
| Dideoxynucleosides | 1 | 2016 | 9 | 0.130 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2016 | 6 | 0.130 |
Why?
|
| Emtricitabine | 1 | 2016 | 8 | 0.130 |
Why?
|
| HIV Core Protein p24 | 1 | 2016 | 17 | 0.130 |
Why?
|
| Tenofovir | 1 | 2016 | 8 | 0.130 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2016 | 18 | 0.130 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2016 | 19 | 0.130 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2016 | 11 | 0.130 |
Why?
|
| Esophageal Diseases | 1 | 2016 | 16 | 0.130 |
Why?
|
| HIV-2 | 1 | 2016 | 23 | 0.130 |
Why?
|
| Anus Neoplasms | 1 | 2016 | 23 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 93 | 0.130 |
Why?
|
| Candidiasis | 1 | 2016 | 40 | 0.130 |
Why?
|
| Sarcoma, Kaposi | 1 | 2016 | 17 | 0.130 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2016 | 94 | 0.130 |
Why?
|
| Drug Combinations | 1 | 2016 | 138 | 0.130 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2016 | 38 | 0.130 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 51 | 0.130 |
Why?
|
| Thrombocytopenia | 1 | 2016 | 49 | 0.120 |
Why?
|
| Lymphoma | 1 | 2016 | 100 | 0.120 |
Why?
|
| Criminal Law | 1 | 2016 | 91 | 0.120 |
Why?
|
| HIV Antibodies | 1 | 2016 | 141 | 0.120 |
Why?
|
| Influenza Vaccines | 1 | 2016 | 88 | 0.120 |
Why?
|
| Papillomavirus Vaccines | 1 | 2016 | 72 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 436 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 492 | 0.120 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 146 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2016 | 127 | 0.110 |
Why?
|
| Influenza, Human | 1 | 2016 | 192 | 0.110 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 272 | 0.100 |
Why?
|
| United States | 2 | 2016 | 7620 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2016 | 744 | 0.100 |
Why?
|
| Male | 5 | 2016 | 27949 | 0.100 |
Why?
|
| Tuberculosis | 1 | 2016 | 268 | 0.100 |
Why?
|
| Insulin Resistance | 1 | 2016 | 406 | 0.100 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2011 | 18 | 0.090 |
Why?
|
| Humans | 7 | 2016 | 60081 | 0.090 |
Why?
|
| Delayed Diagnosis | 1 | 2011 | 43 | 0.090 |
Why?
|
| Adult | 4 | 2016 | 15972 | 0.090 |
Why?
|
| Coinfection | 1 | 2011 | 44 | 0.090 |
Why?
|
| Algorithms | 1 | 2016 | 1006 | 0.090 |
Why?
|
| HIV-1 | 1 | 2016 | 710 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2016 | 1936 | 0.080 |
Why?
|
| Pregnancy | 1 | 2016 | 2361 | 0.080 |
Why?
|
| Risk Factors | 1 | 2016 | 5090 | 0.060 |
Why?
|
| Young Adult | 1 | 2016 | 4398 | 0.060 |
Why?
|
| Adolescent | 1 | 2016 | 5944 | 0.060 |
Why?
|
| Female | 2 | 2016 | 31224 | 0.060 |
Why?
|
| Splenic Diseases | 1 | 2003 | 15 | 0.050 |
Why?
|
| Splenectomy | 1 | 2003 | 41 | 0.050 |
Why?
|
| Drug Utilization Review | 1 | 2003 | 56 | 0.050 |
Why?
|
| Endocarditis, Bacterial | 1 | 2003 | 30 | 0.050 |
Why?
|
| Liposomes | 1 | 2003 | 100 | 0.050 |
Why?
|
| Abscess | 1 | 2003 | 75 | 0.050 |
Why?
|
| Aged | 2 | 2016 | 13594 | 0.050 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2003 | 157 | 0.040 |
Why?
|
| Hospitals | 1 | 2003 | 377 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2003 | 1239 | 0.040 |
Why?
|
| Middle Aged | 1 | 2016 | 16540 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2003 | 401 | 0.040 |
Why?
|
| Antiprotozoal Agents | 1 | 2011 | 8 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2003 | 6147 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 115 | 0.020 |
Why?
|
| Anti-Retroviral Agents | 1 | 2011 | 73 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 2049 | 0.010 |
Why?
|